Metabolic syndrome

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

Retrieved on: 
Mittwoch, Mai 29, 2024
Biometrics, Health, Pharmaceutical, Clinical Trials, Cardiology, Bempedoic acid, Patient, Cardiovascular disease, ATP, ACL, EAS, Risk, ACC, Obesity, Apolipoprotein, University, Diabetes, Metabolic syndrome, Preventive healthcare, Male, Safety, Agent handling, Metabolism, Ezetimibe, Congress, Death, CLEAR, Observational study, Incidence, Woman, Daiichi Sankyo, Human, Hyperuricemia, Metadata, Female, Pharmaceutical industry

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced additional results from prespecified subgroup analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial.

Key Points: 
  • Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced additional results from prespecified subgroup analyses of the Phase 3 CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes trial.
  • In the CLEAR Outcomes subgroup analysis of patients with or without MetS, treatment with bempedoic acid reduced the risk of MACE-4 to a similar extent.
  • “As clinicians, our priority is to reduce LDL-C levels to lower the risk of CV events.
  • Combination therapy with bempedoic acid may be one way to address this issue.”
    “Our goal at Daiichi Sankyo is to help protect people from cardiovascular disease.

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Retrieved on: 
Montag, Mai 13, 2024
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Patient, Weight gain, Positive, Psychosis, PANSS, Metabolic syndrome, Medication, Safety, Clozapine, Evenamide, MD, EPS, CNS, Observation, Clinical Global Impression, Schizophrenia, XETRA, Peripheral nervous system, Blood, ANCOVA, Pharmaceutical industry

Study 008A is the first well-designed study demonstrating efficacy of an adjunctive treatment in benefiting patients who do not respond to their current antipsychotic.

Key Points: 
  • Study 008A is the first well-designed study demonstrating efficacy of an adjunctive treatment in benefiting patients who do not respond to their current antipsychotic.
  • Evenamide also is the first glutamate modulator to demonstrate efficacy in inadequately responding patients with schizophrenia in a placebo-controlled study.
  • Ravi Anand, MD, Chief Medical Officer of Newron, stated: “These new efficacy results from study 008A attest to the clinical relevance of the benefits for patients, based on the primary and key secondary endpoints.
  • Most importantly, the benefits noted on the efficacy measures increased up to Day 29, thus suggesting larger and enduring effects during longer term treatment.

Merck Manuals: The Facts on Fatty Liver and its New Name

Retrieved on: 
Mittwoch, Mai 8, 2024
Liver disease, Fatty liver disease, NAFLD, Blood, Blood pressure, MD, Human, Tholey, Thomas Jefferson University, Obesity, Light, Patient, Editorial, Cholesterol, AASLD, Metabolic syndrome, Insulin resistance, Dietary supplement

She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.

Key Points: 
  • She also explains why doctors are moving away from the term fatty liver towards more detailed terminology.
  • In 2023, the American Association for the Study of Liver Disease (AASLD) updated the nomenclature around steatotic liver disease and fatty liver.
  • Fatty liver due to any condition except consumption of large amounts of alcohol was previously called nonalcoholic fatty liver disease (NAFLD).
  • Tholey stresses even social drinking can have a negative effect, and it's not just hard alcohol that can lead to fatty liver.

RxSugar® and SiPhox Health Partner to Combat the Epidemic of Diet-related Disease

Retrieved on: 
Dienstag, Mai 7, 2024
Conditional sentence, Cancer, Inflammation, DSM-IV codes, Metabolic syndrome, CDC, Health, Microfluidics, Silicon, Death, Diabetes, Biochemistry, Partnership, Intel Capital, Research, Y Combinator, Metabolism, Khosla, Disease, Psicose, Silicon photonics, Cardiovascular disease, Biomarker, Sugar, Disability, Medical device

BURLINGTON, Mass., May 7, 2024 /PRNewswire/ -- RxSugar® and SiPhox Health are partnering to deliver solutions to combat the epidemic of diet-related disease.

Key Points: 
  • BURLINGTON, Mass., May 7, 2024 /PRNewswire/ -- RxSugar® and SiPhox Health are partnering to deliver solutions to combat the epidemic of diet-related disease.
  • SiPhox Health is a well-recognized industry leader in the development of home biomarker testing solutions.
  • Extensive research, including non-clinical and human studies, substantiates Allulose's significant role in vital physiological functions pertinent to cardiometabolic health [references].
  • The SiPhox platform allows members to routinely test a wide array of traditional biomarkers providing a holistic snapshot of their comprehensive health and risk of disease.

MEDIROM Healthcare Technologies Inc. Announces March 2024 Key Performance Indicators (KPIs)

Retrieved on: 
Donnerstag, April 25, 2024
Information and communications technology, Risk, ICT, Habit, Exercise, Smoking, Diet, Ministry, Metabolic syndrome, Sleep, COVID-19, Beauty salon

(*2) Number of Salons with Data: The number of salons for which comparable financial and customer data is available.

Key Points: 
  • (*2) Number of Salons with Data: The number of salons for which comparable financial and customer data is available.
  • (*3) Total Customers Served: The number of customers served at salons for which comparative financial and customer data is available.
  • (*4) Sales Per Customer: The ratio of total salon sales to number of treated customers at all salons for which comparable financial and customer data is available.
  • In March 2024, the repeat ratios for all salons and salons in public bathhouses only were 77.9% and 57.1%, respectively.

First National Study to Assess the Prevalence of NAFLD to be Conducted by Federal Government

Retrieved on: 
Donnerstag, April 25, 2024
Congress, Fatty liver disease, ALF, Language, NAFLD, Liver disease, Risk, Hispanic, AHRQ, Overweight, Diabetes, FAST, Partnership, Agency, Research, American Liver Foundation, Disease, Obesity, Labour, NASH, Patient, Liver failure, Society, Metabolic syndrome, American Society of Transplantation, Liver transplantation, Prevalence, Dietary supplement

NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.

Key Points: 
  • NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
  • New national study to assess prevalence of NAFLD to be conducted, ALF grateful to Congress and advocates.
  • "We are so grateful to Senator Bill Cassidy (R-LA) for his leadership in championing this effort on Capitol Hill.
  • In an online liver health quiz to assess risk factors, 93% of respondents received a positive result for being at risk for NAFLD.

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Montag, März 25, 2024
Research, Diabetic nephropathy, Cholesterol, Obesity, Institutional review board, Patient, Protocol, MJFF, University, IND, IRB, Investigational New Drug, Therapy, Atherosclerosis, Metabolic syndrome, Government, Inflammasome, Pharmaceutical industry

WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.

Key Points: 
  • Scientific collaboration to assess Inflammasome ASC Inhibitor IC 100 as a potential treatment for atherosclerosis expected to conclude H1-2024.
  • WESTON, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for full year ending December 31, 2023, and provides business update.
  • “Throughout 2023 and early 2024, ZyVersa achieved considerable progress in advancing development of our two lead candidates.
  • The impairment is a result of the decline in stock value and the resulting market capitalization of ZyVersa during the 2023 Period.

Ketogenic Diet Shows Promise in Treating Serious Mental Illness in Stanford Medicine Study

Retrieved on: 
Montag, April 1, 2024
Overweight, Metabolism, Adipose tissue, Obesity, Schizophrenia, Dyslipidemia, McLean Hospital, Weight gain, Patient, SAN, Mental health, Sleep, Research, University, MD, Quality of life, Eating disorder, DSM-IV codes, Insulin resistance, Body mass index, Clinical trial, Metabolic syndrome, University of Edinburgh, Rethinking, Mood disorder, Psychiatry Research, Ketosis, Waist, BMI, Pharmaceutical industry

SAN MATEO, Calif., April 1, 2024 /PRNewswire/ -- The field of psychiatry may have a new ally in the form of a medical ketogenic diet, according to the findings of a pioneering pilot study published in Psychiatry Research and announced today by Stanford Medicine. The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965. 

Key Points: 
  • The study, supported by funding from Baszucki Group and others, is the first U.S.-based clinical trial to examine the therapeutic impact of a ketogenic dietary intervention for serious mental illness since 1965.
  • The results offer compelling evidence of the potential benefits of ketogenic dietary therapy in this population.
  • Key findings of the single-arm pilot trial include:
    100% of participants who met the criteria for metabolic syndrome were in remission by the end of the study.
  • Dr. Sethi shared: "These results are encouraging and suggest that a ketogenic diet intervention could serve as a valuable adjunctive treatment for individuals living with serious mental illness.

What is metabolism? A biochemist explains how different people convert energy differently − and why that matters for your health

Retrieved on: 
Freitag, April 5, 2024
Blood pressure, Agonal respiration, Dicarboxylic acid, Kynurenine, Health, Metabolism, Burn, COVID, Obesity, Sport, Exercise, Cell, Multiple sclerosis, Diabetes, COVID-19, Patient, Inflammation, Social media, Mitochondrion, Fats, Electron, Radiation exposure, Food, Carbohydrate, Smoke, Anti-transglutaminase antibodies, Medicine, Protein, Athlete, Carbon, Coenzyme A, Phenotype, Oxygen, Metabolic syndrome, BMI, Blood, Ageing, Medical device

But what exactly is your metabolism?

Key Points: 
  • But what exactly is your metabolism?
  • Everything you expose your body to – from lifestyle to an airborne virus – influences your physical characteristics, such as your blood pressure and energy levels.

Metabolism is energy conversion

  • At the chemical level, energy metabolism begins when the three macronutrients – carbohydrates, fats and protein – are broken down atom by atom to release electrons from chemical bonds.
  • Simply put, a primary role of metabolism is to convert chemical energy into electrical energy and back into chemical energy.
  • I am a biochemist who studies the various networks of metabolism that are used as your body changes.
  • My team and I have been able to define specific traits of metabolism, such as the presence and amount of certain metabolites – products made from breaking down macronutrients – across a wide range of conditions.

Elite athletes define the upper limits

  • Elite athletes offer a prime population to study metabolic function at its best, since their network of molecular and chemical reactions must be finely tuned to compete on the world stage.
  • Traditionally, lactate threshold has been a critical measure of athletic performance by pinpointing exercise intensity when lactate starts to rise in muscles and blood.
  • When comparing the lactate thresholds of a group of elite cyclists, we found that the cyclists with higher thresholds had markers of better mitochondrial function.

Dysfunctional metabolism in diseases like COVID-19

  • Your metabolism also changes if you get an acute illness such as COVID-19.
  • In contrast to elite cyclists, COVID-19 patients have an impaired ability to burn fat that appears to persist with long COVID.


Burning fat uses a lot of oxygen. COVID-19 damages the red blood cells that deliver oxygen to organs. Because red blood cells have a limited ability to repair themselves, they might not function as well during the remainder of their roughly 120-day life span. This may partially explain why COVID symptoms last as long as they do in some people.

Blood donors define the middle

  • Blood donors, coming from every walk of life, also have a diverse range of biological traits as a study population.
  • My team and I looked at blood from over 13,000 blood donors to shed light on their metabolic diversity.
  • We found that blood from donors with higher levels of kynurenine was less likely to restore hemoglobin levels in transfusion recipients compared with donors with lower kynurenine levels.


In addition to his appointment at the University of Colorado, Travis Nemkov is an Affiliate Investigator of Vitalant Research Institute and a co-founder of Omix Technologies.

Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System

Retrieved on: 
Dienstag, März 5, 2024
Technology, Medical Devices, FDA, Clinical Trials, Health Technology, Cardiology, Software, Health, Artificial Intelligence, Diabetes, Prediabetes, Randomized controlled trial, Physician, Food, Stenosis, MACE, Coronary artery disease, Lung, Splenic infarction, Risk, TAP, CAD, Atherosclerosis, Ischemia, Risk assessment, Metabolic syndrome, Patient, MPH, Medicine, Diagnosis, Heart, CTS, Medical device

Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System.

Key Points: 
  • Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its Coronary Artery Disease (CAD) Staging System.
  • The CAD Staging System is a noninvasive imaging-based investigational software device that analyzes important and actionable features of coronary atherosclerosis, stenosis and ischemia.
  • The FDA’s Breakthrough Device Designation is granted for technologies that have the possibility to encourage more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases.
  • “This designation from the FDA highlights the critical need for better heart disease risk assessment methods.